Company intelligence / Profile preview

Convergent Genomics

Portland, Oregon, United Statesconvergentgenomics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Convergent Genomics has developed UroAmp, a non-invasive urine-based genomic test that leverages next-generation sequencing and machine learning to detect bladder cancer and predict its recurrence months or years before it becomes clinically apparent. Clinical studies have shown that UroAmp can identify both high-grade and low-grade tumors missed by cytology, providing actionable insights for clinicians managing urothelial cancers[1][5].

Therapeutic areas: Oncology
Modalities: Diagnostic testNext-generation sequencingLiquid biopsy (urine DNA-based)
Industry: Molecular Diagnostics

Drug pipeline

1 asset

UroAmp

Commercial

Indications: Bladder cancer

Partnerships

Not publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Convergent Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Convergent Genomics.

Explore the full profile